ShaymaMaster(Master)KazmiMDRPh(She/Her)

Oncology • Cherry Hill, NJ

Breast Cancer, Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Oncologist/Hematologist

Join to view full profile

Dr. Kazmi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kazmi's full profile

Already have an account?

Office
1865 NJ-70 E
Cherry Hill, NJ 08003
Phone+1 856-429-1519

Fax+1 856-427-0250
Is this information wrong?

Education & Training

Rutgers Health/Robert Wood Johnson Medical SchoolFellowship, Hematology and Medical Oncology, 2004 - 2007
Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 2001 - 2004
Rutgers Robert Wood Johnson Medical SchoolClass of 2001
Rutgers University, College of PharmacyBS, Pharmacy, With High Honors, 1992 - 1997

Certifications & Licensure

NJ State Medical License 1997 - 2025
PA State Medical License 2009 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Outstanding Participation-Development & Implementation of Clinical Pathways 2016
Patient's Choice Award 2012
Compassionate Doctor Recognition 2012
Women of Accomplishment Greater Philadelphia Yellow Pages, 2011
Join now to see all

Clinical Trials

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer Start of enrollment: 2008 Jun 01
Unknown status
Phase 1, Phase 2
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer Start of enrollment: 2009 Feb 04
Completed
Phase 2
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2010 May 01
No longer available
Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer Start of enrollment: 2012 Oct 19
Completed
Phase 2
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Start of enrollment: 2014 Apr 14
Completed
Phase 2
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. Start of enrollment: 2014 Jul 28
Completed
Phase 1
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
No longer available
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) Start of enrollment: 2015 Jun 11
Completed
Phase 2
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Start of enrollment: 2015 Aug 24
Completed
Phase 3
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Start of enrollment: 2015 Nov 19
Active, not recruiting
Phase 2
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer Start of enrollment: 2016 Jan 28
Completed
Phase 2
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) Start of enrollment: 2016 Feb 25
Completed
Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Start of enrollment: 2016 Mar 14
Recruiting
Phase 2
A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2016 Sep 23
Completed
Phase 2
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Start of enrollment: 2017 Mar 17
Active, not recruiting
Phase 2
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2017 Jun 01
Completed
Phase 2, Phase 3
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation Start of enrollment: 2017 Oct 13
Terminated
Phase 2
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Start of enrollment: 2018 Apr 24
Active, not recruiting
Phase 3
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer Start of enrollment: 2018 Jun 28
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Shayma Kazmi, Debanjana Chatterjee, Dheeraj Raju, Rob Hauser, Peter A Kaufman> ;Breast Cancer Research and Treatment. 2021 Jun 1
6 citations
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Shayma Kazmi, Debanjana Chatterjee, Dheeraj Raju, Rob Hauser, Peter A Kaufman> ;Breast Cancer Research and Treatment. 2020 Nov 1
3 citations
Malignant phyllodes tumor in Lynch syndrome: a case report
Shayma Kazmi, Steven Wagner, Rebecca C. Heintzelman, Melanie Corbman> ;Journal of Medical Case Reports. 2019 Jul 16

Abstracts/Posters

Therapeutic Efficacy of Off-Label Targeted Agents Utilization Based Molecular Profiling in Advanced Cancer Patients.
Ricardo H. Alvarez, Rebecca Rollins, Joe Ensor Jr, Amber Moran, Evan Pisick, Sramila Aithal, Eyal Meiri, Patricia Rich, Shayma Kazmi, Laura Farrington, Pamela Criley, ..., American Society of Clinical Oncology (ASCO), 1/1/2018
A Retrospective Analysis to evaluate prevalence and correlation between PD-L1 score and Tumor Mutational Burden levels in Patients with Solid Tumor Malignancies.
Shayma Kazmi, European Society of Medical Oncology Immuno Oncology 2017, Geneva, Switzerland, 1/1/2017
A Retrospective Analysis of Response to Checkpoint Inhibitors and its correlation to both PD-L1 score and Tumor Mutational Burden in Patients with Solid Tumor Malignan...
Shayma Kazmi, European Society of Medical Oncology Immuno Oncology 2017, Geneva, Switzerland, 1/1/2017
Evaluation of Novel Blood-Based Biomarkers with Atezolizumab Monotherapy in 1L Advanced or Metastatic NSCLC (B-FIRST).
M. Socinski, J. Schiller, S. Dakhil, S. Kazmi, J. Leach, S. Hu, et. al., Journal of Clinical Oncology, 1/1/2016
Evaluation of novel blood-based biomarkers with atezolizumab monotherapy in 1L advanced or metastatic NSCLC (B-F1RST).
Mark A. Socinski, Joan Schiller, Shaker Dakhil, Shayma Kazmi, Joseph Leach, Sylvai Hu, Sarah Paul, David Shames, See Phan, Cindy Yun, Vamsidhar Velcheti, International Association for the Study of Lung Cancer (IASLC), Chicago, IL, 1/1/2016
Clinical Activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients with Stage III/IV non-small cell lung cancer.
Shayma Kazmi, BIND Therapeutics Poster Presentation at 26thth EORTC-NCI-AACR, Symposium on Molecular Targets & Cancer Therapeutics, Barcelona, Spain, 1/1/2014
Join now to see all

Lectures

Decision Points in Advanced Non Small Cell Lung Cancer
Terre Haute, IN - 1/1/2018
Advances in Non Small Cell Lung Cancer Treatment
Philadelphia, PA - 1/1/2017
Role of PCP in cancer care.
1/1/2016
Truth or Dare
New York City - 1/1/2015
Metastatic & Triple Negative Breast Cancer
Houston, TX - 1/1/2015
Integrative approach to Cancer Management
DC - 1/1/2015
Genomic Medicine: The Future of Cancer Care.
1/1/2014
Genomic Medicine
Westchester, NY - 1/1/2014
Join now to see all

Other

Genomics
Shayma Kazmi, Time Magazine
1/1/2015
"Breast Cancer"
Shayma Kazmi, ABC News Webchat
1/1/2014
"Genomics & Patient Empowered Care"
Shayma Kazmi, 2 National Commercials, Cancer Treatment Centers of America (CTCA)
1/1/2013
Patient Empowerment Care Model
Shayma Kazmi, NBC News Commercial
1/1/2012
Chemotherapy shortages.
Shayma Kazmi, FOX29 News
1/1/2012
Did Joe Paterno lose the will to live?
Shayma Kazmi, ABC News
1/1/2012
IVF and Cancer Risk
Shayma Kazmi, Article, Parents Magazine
1/1/2011
IVF and Breast Cancer
Shayma Kazmi, FOX29 News
1/1/2011
Survivor? No, She's a Cancer Fighter
Shayma Kazmi, Article, The Philadelphia Tribune
1/1/2011
Union Square Yoga Class Gives Hope to Breast Cancer Survivors
Shayma Kazmi, DNAInfo
1/1/2011
United States Considers Stockpile
Shayma Kazmi, Article, Canadian Medical Association Journal
1/1/2011
Drug Shortages
Shayma Kazmi, FOX29 News
1/1/2011
High Stress Could Cause Cancer
Shayma Kazmi, NBC Philadelphia News
1/1/2009
Join now to see all

Press Mentions

Breathe EasyNovember 27th, 2019
Genomic Medicine: The Future of Cancer Treatment Is NowJuly 23rd, 2017
What Your Doctor Wants You to Ask About Metastatic Breast CancerFebruary 11th, 2018

Committees

Member, Thoracic Leadership Committee 2021 - Present

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
International association of study of lung cancer
Member
ESMO European society of medical oncology
Member
American Lung Association
Board Member
Society of Immunotherapy in Cancer
Member

Other Languages

Hindi, Gujarati